CoChat

Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021

Bakari, Catherine, Mandara, Celine I., Madebe, Rashid A., Seth, Misago D., Ngasala, Billy, Kamugisha, Erasmus, Ahmed, Maimuna, Francis, Filbert, Bushukatale, Samwel, Chiduo, Mercy, Makene, Twilumba, Kabanywanyi, Abdunoor M., Mahende, Muhidin K., Kavishe, Reginald A., Muro, Florida, Mkude, Sigsbert, Mandike, Renata, Molteni, Fabrizio, Chacky, Frank, Bishanga, Dunstan R., Njau, Ritha J. A., Warsame, Marian, Kabula, Bilali, Nyinondi, Ssanyu S., Lucchi, Naomi W., Talundzic, Eldin, Venkatesan, Meera, Moriarty, Leah F., Serbantez, Naomi, Kitojo, Chonge, Reaves, Erik J., Halsey, Eric S., Mohamed, Ally, Udhayakumar, Venkatachalam, Ishengoma, Deus S. · 2024 · Malaria Journal
Cited by 29

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background: Therapeutic efficacy studies (TESs) and detection of molecular markers of drug resistance are recommended by the World Health Organization (WHO) to monitor the efficacy of artemisinin-based combination therapy (ACT). This study assessed the trends of molecular markers of artemisinin resistance and/or reduced susceptibility to lumefantrine using samples collected in TES conducted in Mainland Tanzania from 2016 to 2021. Methods: A total of 2,015 samples were collected during TES of artemether-lumefantrine at eight sentinel sites (in Kigoma, Mbeya, Morogoro, Mtwara, Mwanza, Pwani, Tabora, and Tanga regions) between 2016 and 2021. Photo-induced electron transfer polymerase chain reaction (PET-PCR) was used to confirm presence of malaria parasites before capillary sequencing, which targeted two genes: Plasmodium falciparum kelch 13 propeller domain ( k13 ) and P. falciparum multidrug resistance 1 ( pfmdr1 ). Results: Sequencing success was ≥ 87.8%, and 1,724/1,769 (97.5%) k13 wild-type samples were detected. Thirty-seven (2.1%) samples had synonymous mutations and only eight (0.4%) had non-synonymous mutations in the k13 gene; seven of these were not validated by the WHO as molecular markers of resistance. One sample from Morogoro in 2020 had a k13 R622 I mutation, which is a validated marker of artemisinin partial resistance. For pfmdr1, all except two samples carried N86 (wild-type), while mutations at Y184 F increased from 33.9% in 2016 to about 60.5% in 2021, and only four samples (0.2%) had D1246 Y mutations. pfmdr1 haplotypes were reported in 1,711 samples, with 985 (57.6%) NYD, 720 (42.1%) N F D, and six (0.4%) carrying minor haplotypes (three with NY Y , 0.2%; Y F D in two, 0.1%; and N FY in one sample, 0.1%). Between 2016 and 2021, NYD decreased from 66.1% to 45.2%, while N F D increased from 38.5% to 54.7%. Conclusion: This is the first report of the R622I (k13 validated mutation) in Tanzania. N86 and D1246 were nearly fixed, while increases in Y184 F mutations and N F D haplotype were observed between 2016 and 2021. Despite the reports of artemisinin partial resistance in Rwanda and Uganda, this study did not report any other validated mutations in these study sites in Tanzania apart from R622I suggesting that intensified surveillance is urgently needed to monitor trends of drug resistance markers and their impact on the performance of ACT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12936-024-04896-0

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Map of Tanzania showing the regions and the eight National Malaria Control Programme sentinel sites
Fig. 1 Map of Tanzania showing the regions and the eight National Malaria Control Programme sentinel sitesCC BY · PubMed Central
Fig. 2 Trend of 184F mutation in the eight regions of Mainland Tanzania from 2016 to 2021
Fig. 2 Trend of 184F mutation in the eight regions of Mainland Tanzania from 2016 to 2021CC BY · PubMed Central
Fig. 3 Trend of pfmdr1 NYD haplotype in the eight regions of Mainland Tanzania from 2016 to 2021
Fig. 3 Trend of pfmdr1 NYD haplotype in the eight regions of Mainland Tanzania from 2016 to 2021CC BY · PubMed Central
Fig. 4 Trend of pfmdr1 NFD haplotype in the eight regions of Mainland Tanzania from 2016 to 2021
Fig. 4 Trend of pfmdr1 NFD haplotype in the eight regions of Mainland Tanzania from 2016 to 2021CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 32

  1. Uwimana A Umulisa N Venkatesan M Svigel SS Zhou Z Munyaneza T Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study Lancet Infect Dis 2021 21 1120 1128 10.1016/S1473-3099(21)00142-0 33864801 PMC10202849 · DOI · Paper page
  2. Balikagala B Fukuda N Ikeda M Katuro OT Tachibana S-I Yamauchi M Evidence of Artemisinin-Resistant Malaria in Africa N Engl J Med 2021 385 1163 1171 10.1056/NEJMoa2101746 34551228 · DOI · Paper page
  3. Mihreteab S Platon L Berhane A Stokes BH Warsame M Campagne P Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea N Engl J Med 2023 389 1191 1202 10.1056/NEJMoa2210956 37754284 PMC10539021 · DOI · Paper page
  4. Conrad MD Asua V Garg S Giesbrecht D Niaré K Smith S Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda N Engl J Med 2023 389 722 732 10.1056/NEJMoa2211803 37611122 PMC10513755 · DOI · Paper page
  5. Ishengoma DS, Mandara CI, Bakari C, Fola AA, Madebe RA, Seth MD, et al. Evidence of artemisinin partial resistance in North-western Tanzania: clinical and drug resistance markers study. medRxiv. 2024; 10.1101/2024.01.31.24301954. · doi:10.1101/2024.01.31.24301954
  6. Blasco B Leroy D Fidock DA Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic Nat Med 2017 23 917 928 10.1038/nm.4381 28777791 PMC5747363 · DOI · Paper page
  7. Ishengoma DS Saidi Q Sibley CH Roper C Alifrangis M Deployment and utilization of next-generation sequencing of Plasmodium falciparum to guide anti-malarial drug policy decisions in sub-Saharan Africa: Opportunities and challenges Malar J 2019 18 267 10.1186/s12936-019-2853-4 31477109 PMC6719357 · DOI
  8. Hodoameda P. P. falciparum and Its Molecular Markers of Resistance to Antimalarial Drugs. Plasmodium species and drug resistance. IntechOpen; 2021. · doi:10.5772/intechopen.98372
  9. Juliano JJ, Giesbrecht DJ, Simkin A, Fola AA, Lyimo BM, Pereus D, et al. Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania. bioRxiv. 2023. Available from: https://www.medrxiv.org/content/10.1101/2023.11.07.23298207v1. · doi:10.1101/2023.11.07.23298207v1
  10. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833–43. PMC4183414 25048375 · DOI · Paper page
  11. Malmberg M Ngasala B Ferreira PE Larsson E Jovel I Hjalmarsson A Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district Tanzania Malar J 2013 12 103 10.1186/1475-2875-12-103 23506218 PMC3732084 · DOI
  12. Shayo A Buza J Ishengoma DS Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania Malar J 2015 14 135 10.1186/s12936-015-0649-8 25889242 PMC4415202 · DOI
  13. Kakolwa MA Mahende MK Ishengoma DS Mandara CI Ngasala B Kamugisha E Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania Malar J 2018 17 369 10.1186/s12936-018-2524-x 30333022 PMC6192314 · DOI
  14. Mandara CI Francis F Chiduo MG Ngasala B Mandike R Mkude S High cure rates and tolerability of artesunate–amodiaquine and dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Kibaha and Kigoma Tanzania Malar J 2019 18 1 12 PMC6434871 30909922
  15. Halsey ES Venkatesan M Plucinski MM Talundzic E Lucchi NW Zhou Z Capacity Development through the US President’s Malaria Initiative-Supported Antimalarial Resistance Monitoring in Africa Network Emerg Infect Dis 2017 23 S53 S56 10.3201/eid2313.170366 29155671 PMC5711327 · DOI · Paper page
  16. Ishengoma DS Mandara CI Francis F Talundzic E Lucchi NW Ngasala B Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania Malar J 2019 18 88 10.1186/s12936-019-2730-1 30898164 PMC6427902 · DOI
  17. Lucchi NW Karell MA Journel I Rogier E Goldman I Ljolje D PET-PCR method for the molecular detection of malaria parasites in a national malaria surveillance study in Haiti, 2011 Malar J 2014 13 462 462 10.1186/1475-2875-13-462 25428550 PMC4289323 · DOI
  18. Talundzic E, Chenet SM, Goldman IF, Patel DS, Nelson JA, Plucinski MM, et al. Genetic analysis and species specific amplification of the artemisinin resistance-associated kelch propeller domain in P. falciparum and P. vivax. PLoS One. 2015;10:e0136099. PMC4546394 26292024 · DOI · Paper page
  19. Ngasala B, Chiduo MG, Bushukatale S, Mmbando BP, Makene T, Kamugisha E, et al. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2018. Research Square. 2024[cited 2024 Jan 17]; Available from: https://www.researchsquare.com/article/rs-3520720/v1. PMC10998292 38582830 · doi:10.21203/rs.3.rs-3786283/v1
  20. Ngasala BE, Chiduo MG, Mmbando BP, Francis FT, Bushukatale S, Makene T, et al. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2019. Research Square. 2024[cited 2024 Jan 17]; Available from: https://www.researchsquare.com/article/rs-3786283/v1. PMC11005286 38594679 · doi:10.21203/rs.3.rs-3786283/v1
  21. Moser KA, Madebe RA, Aydemir O, Chiduo MG, Mandara CI, Rumisha SF, et al. Describing the current status of Plasmodium falciparum population structure and drug resistance within mainland Tanzania using molecular inversion probes. Mol Ecol. 2020;mec.15706 – mec.15706. PMC8088766 33107096 · doi:10.1101/2020.05.09.085225
  22. Schmedes SE Patel D Dhal S Kelley J Svigel SS Dimbu PR Plasmodium falciparum kelch 13 Mutations, 9 Countries in Africa, 2014–2018 Emerg Infect Dis 2021 27 1902 1908 10.3201/eid2707.203230 34152946 PMC8237877 · DOI
  23. Ndwiga L Kimenyi KM Wamae K Osoti V Akinyi M Omedo I A review of the frequencies of Plasmodium falciparum kelch 13 artemisinin resistance mutations in Africa Int J Parasitol Drugs Drug Resist 2021 16 155 161 10.1016/j.ijpddr.2021.06.001 34146993 PMC8219943 · DOI
  24. Bayih AG Getnet G Alemu A Getie S Mohon AN Pillai DR A Unique Plasmodium falciparum kelch 13 Gene Mutation in Northwest Ethiopia Am J Trop Med Hyg 2016 94 132 10.4269/ajtmh.15-0477 26483118 PMC4710417 · DOI · Paper page
  25. Alemayehu AA, Castaneda-Mogollon D, Tesfa H, Getie S, Mohon AN, Balasingam N, et al. Expansion of the Plasmodium falciparum kelch 13 R622I mutation in Northwest Ethiopia. 2021 [cited 2024 Feb 27]; Available from: https://www.researchsquare.com/article/rs-171038. PMC12130971 40463829 · DOI · Paper page
  26. Rogier E, Battle N, Bakari C, Seth MD, Nace D, Herman C, et al. Plasmodium falciparum pfhrp2 and pfhrp3 gene deletions among patients enrolled at 100 health facilities throughout Tanzania: February to July 2021. medRxiv. 2023 [cited 2023 Dec 7]; Available from: https://www.medrxiv.org/content/10.1101/2023.07.29.23293322. PMC11001933 38589477 · doi:10.1101/2023.07.29.23293322
  27. Bwire GM Ngasala B Mikomangwa WP Kilonzi M Kamuhabwa AAR Detection of mutations associated with artemisinin resistance at k13-propeller gene and a near complete return of chloroquine susceptible falciparum malaria in Southeast of Tanzania Sci Rep 2020 10 3500 10.1038/s41598-020-60549-7 32103124 PMC7044163 · doi:10.1038/s41598-020-60549-7
  28. Adamu A Jada MS Haruna HMS Yakubu BO Ibrahim MA Balogun EO Plasmodium falciparum multidrug resistance gene-1 polymorphisms in Northern Nigeria: implications for the continued use of artemether-lumefantrine in the region Malar J 2020 19 439 10.1186/s12936-020-03506-z 33256739 PMC7708160 · doi:10.1186/s12936-020-03506-z
  29. Kay K Goodwin J Ehrlich H Ou J Freeman T Wang K Impact of drug exposure on resistance selection following artemether-lumefantrine treatment for malaria in children with and without HIV in Uganda Clin Pharmacol Ther 2023 113 660 669 10.1002/cpt.2768 36260349 PMC9981240 · doi:10.1002/cpt.2768
  30. Hailemeskel E Menberu T Shumie G Behaksra S Chali W Keffale M Prevalence of Plasmodium falciparum Pfcrt and Pfmdr1 alleles in settings with different levels of Plasmodium vivax co-endemicity in Ethiopia Int J Parasitol Drugs Drug Resist 2019 11 8 12 10.1016/j.ijpddr.2019.09.002 31539706 PMC6796752 · DOI · Paper page
  31. Lobo E de Sousa B Rosa S Figueiredo P Lobo L Pateira S Prevalence of pfmdr1 alleles associated with artemether-lumefantrine tolerance/resistance in Maputo before and after the implementation of artemisinin-based combination therapy Malar J 2014 13 300 10.1186/1475-2875-13-300 25098280 PMC4248432 · DOI
  32. Konaté-Touré A, Gnagne AP, Bedia-Tanoh AV, Menan EIH, Yavo W. Increase of Plasmodium falciparum parasites carrying lumefantrine-tolerance molecular markers and lack of South East Asian pfk13 artemisinin-resistance mutations in samples collected from 2013 to 2016 in Côte d’Ivoire. J Parasit Dis. 2024; Available from: 10.1007/s12639-023-01640-4. PMC10908703 38440764 · doi:10.1007/s12639-023-01640-4

Cited by

See all 29

Metadata

Authors
Bakari, C., Mandara, C. I., Madebe, R. A., Seth, M. D., Ngasala, B., Kamugisha, E., Ahmed, M., Francis, F., Bushukatale, S., Chiduo, M., Makene, T., Kabanywanyi, A. M., Mahende, M. K., Kavishe, R. A., Muro, F., Mkude, S., Mandike, R., Molteni, F., Chacky, F., Bishanga, D. R., Njau, R. J. A., Warsame, M., Kabula, B., Nyinondi, S. S., Lucchi, N. W., Talundzic, E., Venkatesan, M., Moriarty, L. F., Serbantez, N., Kitojo, C., Reaves, E. J., Halsey, E. S., Mohamed, A., Udhayakumar, V., & Ishengoma, D. S.
Venue
Malaria Journal
Published
2024-03-09
Volume
23
Issue
1
ISSN
1475-2875
Cited by
29
References
1
Language
en
Licence
Funders
The US President’s Malaria Initiative supported the TES which generated the data for this study

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021. https://app.cochat.ai/papers/10.1186/s12936-024-04896-0
The paper
Bakari, C., Mandara, C. I., Madebe, R. A., Seth, M. D., Ngasala, B., Kamugisha, E., Ahmed, M., Francis, F., Bushukatale, S., Chiduo, M., Makene, T., Kabanywanyi, A. M., Mahende, M. K., Kavishe, R. A., Muro, F., Mkude, S., Mandike, R., Molteni, F., Chacky, F., . . . Ishengoma, D. S. (2024). Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021. Malaria Journal. https://doi.org/10.1186/s12936-024-04896-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.